Antimicrobial Dosing in Obesity: Finding the Holy Scale
Track:
Education Sessions (CE)
Program Code: 209-L01
Date: Wednesday, December 5, 2012
Time: 4:00 PM to 5:00 PM EST
Location:
Mandalay Bay D, Level 2, South Convention Center
PRESENTER:
Click the plus sign to see more detailed information about each speaker.
Manjunath Pai, PharmD, Associate Professor, Albany College of Pharmacy and Health Sciences
Dr. Pai's research focus is broadly aligned with the discipline of personalized medicine. His specific clinical translational research studies have included the use of in vitro and in
vivo models to aid antimicrobial dose optimization. He has completed clinical pharmacokinetic studies for select antimicrobials in special populations such as patients with HIV, Cystic Fibrosis, and Obesity. His current funded research program includes
identification of the most appropriate body size descriptor to scale drug doses across the adult clinical weight spectrum (30-300 kg). This program includes development of an obese overfed animal model that mimics physiologic changes associated with
human obesity. This model will specifically aid evaluation of the relationship between drug exposure and toxicity in the setting of obesity. Dr. Pai has authored over 50 peer reviewed
manuscripts, 50 scientific abstracts, and 10 chapters. He serves as co-editor of Drug Interactions in Infectious Diseases, Third Edition. Editors: Piscitelli S, Rodvold KA, Pai MP. Springer, New York, NY. He was awarded a Regulatory Science Excellence Award in 2011 from the US Food and Drug Administration for, a more efficient and accurate adjustment of dose for renally cleared drugs across body weight
strata".
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Manjunath Pai, PharmD, Associate Professor, Albany College of Pharmacy and Health Sciences
Dr. Pai's research focus is broadly aligned with the discipline of personalized medicine. His specific clinical translational research studies have included the use of in vitro and in
vivo models to aid antimicrobial dose optimization. He has completed clinical pharmacokinetic studies for select antimicrobials in special populations such as patients with HIV, Cystic Fibrosis, and Obesity. His current funded research program includes
identification of the most appropriate body size descriptor to scale drug doses across the adult clinical weight spectrum (30-300 kg). This program includes development of an obese overfed animal model that mimics physiologic changes associated with
human obesity. This model will specifically aid evaluation of the relationship between drug exposure and toxicity in the setting of obesity. Dr. Pai has authored over 50 peer reviewed
manuscripts, 50 scientific abstracts, and 10 chapters. He serves as co-editor of Drug Interactions in Infectious Diseases, Third Edition. Editors: Piscitelli S, Rodvold KA, Pai MP. Springer, New York, NY. He was awarded a Regulatory Science Excellence Award in 2011 from the US Food and Drug Administration for, a more efficient and accurate adjustment of dose for renally cleared drugs across body weight
strata".
Given a specific obese patient case, evaluate the effects of body size descriptors on the estimate of kidney function.
Interpret the population pharmacokinetic model to aid estimation of the optimal dose in an obese patient.
Recommend an appropriate dose of an antimicrobial agent for an infected patient with chronic kidney disease where no guidance is available for dose modification.